Galecto raises $64m to develop fibrosis and cancer treatments
Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus ... Read More
Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment
Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million ... Read More